Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
The plasma lipid and serum uric acid lowering effect of halofenate (MK-185, 1 g/day) was compared with the action of clofibrate (2 g/day) in a double-blind 1-yr study in 23 patients with Type 2, 3, 4, and 5 hyperlipoproteinemia. It could be demonstrated that clofibrate decreased the plasma cholesterol concentration significantly to 75% and the triglyceride concentration to 49% of the placebo period level. Halofenate produced no consistent effect on plasma cholesterol but ther was an average reduction of the plasma triglyceride concentration to 84%, which was, however, not significant. If only the Type 4 patients were taken into account, a mean significant decrease to 47% of the triglyceride concentration was observed during the second 24-week period of treatment. In contrast, halofenate lowered the serum uric acid concentration significatnly to 77% of the placebo period level, whereas the decreasing action of clofibrate was weaker (88%) and of lesser significance.
D000328:Adult; D000368:Aged; D002994:Clofibrate / Q000494:pharmacology*; D004586:Electrophoresis; D006016:Glycolates / Q000494:pharmacology*; D006218:Halofenate / Q000494:pharmacology*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000378:metabolism*; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D012685:Sepharose; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood*
D006016:Glycolates; D008055:Lipids; D014280:Triglycerides; D014527:Uric Acid; D012685:Sepharose; D002994:Clofibrate; D006218:Halofenate